Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2026 Earnings Call Transcript May 12, 2026Capricor Therapeutics, Inc. misses on earnings expectations.
Capricor Therapeutics Inc. (CAPR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | DG Capital Management Dov Gertzulin | 392,096 | $11,919,718 | -6% | 3.65% |
| 2. | Walleye Capital Will England | 177,543 | $5,397,307 | 0.02% | |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 104,361 | $3,172,574 | 0.02% | |
| 4. | 831 | $998,962 | 0.37% | ||
| 5. | Persistent Asset Partners Xin Huang | 19,933 | $605,963 | -62% | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.36 | 2,798,507 | $14,999,997.52 | 7,090,351 | 2024-09-20 | Filing | |
| $2.75 | 410 | $1,127.50 | 31,536 | 2023-10-12 | Filing | |
| $2.83 | 10,000 | $28,300.00 | 26,856 | 2023-10-10 | Filing | |
| $2.82 | 5,083 | $14,334.06 | 31,126 | 2023-10-09 | Filing | |
| $2.84 | 5,000 | $14,200.00 | 5,000 | 2023-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.70 | 25,000 | $792,547.50 | 30,547 | 2026-05-01 | Filing | |
| $31.70 | 25,000 | $792,540.00 | 8,223 | 2026-05-01 | Filing | |
| $32.00 | 7,529 | $240,928.00 | 0 | 2026-04-02 | Filing | |
| $30.12 | 25,000 | $752,935.00 | 30,547 | 2026-03-31 | Filing | |
| $31.03 | 53,735 | $1,667,225.10 | 0 | 2026-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,027,732 | $61,643,053 | 0% | |
| 2. | 566,081 | $17,208,863 | 0% | |
| 3. | 379,214 | $11,528,106 | 0% | |
| 4. | 371,984 | $11,308,313 | 0% | |
| 5. | 320,098 | $9,730,979 | 0% |
News See All
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance
Capricor Therapeutics Inc. (NASDAQ:CAPR) is one of the best hot stocks to buy according to analysts.
13 Best Hot Stocks to Buy According to Analysts
On March 6, Dan Niles, Niles Investment Management founder, joined 'Power Lunch' on CNBC to discuss the broader market sell-off and provide a cautious outlook on the current market environment.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics, Inc. fourth quarter and full year 2025 conference call.
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory
We came across a bearish thesis on Capricor Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2025 Earnings Call Transcript November 10, 2025Capricor Therapeutics, Inc. reports earnings inline with expectations.
13 Best Multibagger Stocks to Invest in Now
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript May 13, 2025Capricor Therapeutics, Inc. misses on earnings expectations.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second (sic) [Fourth] Quarter 2024 Earnings Call. At this time, all participant lines are in listen-only mode.
10 Worst High-Risk High-Reward Growth Stocks To Buy
On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...
Hedge Fund Resource Center